Study of two drug combos for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been newly diagnosed with multiple myeloma (a type of blood cancer).
- You have measurable disease, meaning enough myeloma cells or proteins in your blood, urine, or bone marrow to track during treatment.
- You are considered a good candidate for high-dose chemotherapy and a stem cell transplant.
- You have standard-risk multiple myeloma (not high-risk genetic features like certain chromosome changes).
- Your overall health is fairly good (ECOG performance status 0-2) and your major organs (kidneys, liver, blood counts) are working well enough.
- You have not received more than one cycle of previous treatment for myeloma (except for one cycle of Dara-RVd at MSK).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.